‘Mindshifting’ type 1 diabetes care: Preparing UK services for the era of disease‐modifying therapy

autoantibodies, immunotherapy, teplizumab, type 1 diabetes mellitus Type 1 diabetes has stood apart for over a century as a chronic condition controlled by a single medicine.We now have another option.The approval of teplizumab (Tzield, Sanofi) by NICE 1 for use within the NHS makes it the UK's first diseasemodifying immunotherapy for type 1 diabetes.For diabetes teams, this represents a transition from reactive treatment to early intervention.Realising the benefits will require new pathways for testing, risk communication, monitoring and treatment delivery.